News >

Atezolizumab Approval Sets Stage for Future Drug Development in TNBC

Caroline Seymour
Published: Thursday, Apr 18, 2019

Mariana Chavez Mac Gregor, MD, MSc

Mariana Chavez Mac Gregor, MD, MSc

The impact of the March 2019 FDA approval of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) in patients with locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC) is unmistakable, but according to Mariana Chavez Mac Gregor, MD, MSc, other agents of considerable merit include PARP inhibitors and antibody-drugs conjugates (ADCs).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x